Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | NEK2 | P51955 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15416556 | 0.89 | KDM4E (0.81) | KDM4ECYP2C19HSD17B10NEK2LMNA | |
| SCHEMBL29140146 | 0.84 | KDM4E (0.72) | KDM4ECYP2C19HPGDUSP2NPSR1 | |
| SCHEMBL12639917 | 0.84 | KDM4E (0.72) | KDM4ECYP2C19HPGDRXFP1MAPT | |
| SCHEMBL5190429 | 0.84 | KDM4E (0.72) | KDM4ECYP2C19HPGDUSP2HSD17B10 | |
| SCHEMBL18255118 | 0.84 | KDM4E (0.72) | KDM4ECYP2C19HPGDUSP2HSD17B10 | |
| SCHEMBL28449100 | 0.81 | KDM4E (0.68) | KDM4ECYP2C19HPGDHSD17B10LMNA | |
| SCHEMBL18248384 | 0.81 | KDM4E (0.68) | KDM4ECYP2C19HPGDUSP2NPSR1 | |
| SCHEMBL3875517 | 0.81 | KDM4E (0.68) | KDM4ECYP2C19HPGDUSP2NPSR1 | |
| SCHEMBL12716919 | 0.81 | KDM4E (0.68) | KDM4ECYP2C19HPGDUSP2NPSR1 | |
| SCHEMBL15751660 | 0.81 | KDM4E (0.68) | KDM4ECYP2C19HPGDUSP2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | claimed |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| EP-4650348-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2025-11-19 | — | — | EP | disclosed |
| WO-2024150815-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | 田辺三菱製薬株式会社 | 2024-07-18 | — | — | WO | disclosed |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| CN-116322692-A | Autotaxin inhibitor compounds | 日东制药株式会社 | 2023-06-23 | — | — | CN | disclosed |
| US-20230120185-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-04-20 | — | — | US | disclosed |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-01 | — | — | US | disclosed |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-11-01 | — | — | US | disclosed |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-09 | — | — | US | disclosed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | disclosed |
| EP-1660481-A1 | PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-05-31 | — | — | EP | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| EP-1558598-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | Pfizer Limited (GB) | 2005-08-03 | — | — | EP | disclosed |
| WO-2005016915-A1 | PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-02-24 | — | — | WO | disclosed |
| US-20040162278-A1 | Triazole compounds useful in therapy | PFIZER INC | 2004-08-19 | — | — | US | disclosed |
| WO-2004037809-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| US-20040082079-A1 | Low affinity screening method | GRAFFINITY PHARMACEUTICALS AG. (DE) | 2004-04-29 | — | — | US | disclosed |
| EP-1360489-A1 | LOW AFFINITY SCREENING METHOD | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002063299-A1 | LOW AFFINITY SCREENING METHOD | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | KDM4E 1204/4885CYP2C19 209/4885HPGD 2504/4885 |
| US-20040162278-A1 | Triazole compounds useful in therapy | AVPR2, AVPR1B, AVPR1A | KDM4E 4654/4885CYP2C19 478/4885HPGD 1209/4885 |
| US-20230120185-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | MAP3K19, MAP3K20, MAP3K1 | KDM4E 629/4885CYP2C19 1433/4885HPGD 1822/4885 |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | USP30, USP28, USP1 | KDM4E 298/4885CYP2C19 1330/4885HPGD 2478/4885 |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | USP30, USP28, USP1 | KDM4E 298/4885CYP2C19 1330/4885HPGD 2478/4885 |
| US-11485710-B2 | Heterocyclic amides as kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | KDM4E 629/4885CYP2C19 1433/4885HPGD 1822/4885 |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | KDM4E 482/4885CYP2C19 4083/4885HPGD 4080/4885 |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | KDM4E 2664/4885CYP2C19 2800/4885HPGD 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.